Matrixx launches cold and flu mobile application
SCOTTSDALE, Ariz. Matrixx Initiatives on Tuesday launched the Zicam Cold & Flu Companion mobile application for the T-Mobile G1. The application enables on-the-go consumers to take charge of their health by checking cold and flu activity by zip code, among other features, the company stated.
“The Cold & Flu Companion offers an innovative and customizable resource for consumers to prepare for the cold and flu season,” stated Tim Connors, vice president of marketing at Matrixx Initiatives. “Knowing the latest cold and flu news and understanding the cold, flu and cough activity in a localized area can aid consumers in being aware of the risks around them.”
The service shows users the percentage of sick people in any given zip code, what types of symptoms are most prevalent and which ones to look out for in a specific area. The application also keeps users updated on the latest cold and flu news.
The application also provides a tool to receive coupons for Zicam products and location-based directions identify nearby retailers where products can be purchased and coupons redeemed.
The same mobile application will be released for the iPhone in mid-December.
FDA grants tentative approval for generic version of Zyprexa
ROCKVILLE, Md. The Food and Drug Administration has granted tentative approval to Roxane Labs’ generic version of Eli Lilly and Co.’s antipsychotic drug, Zyprexa, FDA records show.
The FDA passed tentative approval for the generic version of the drug in the 5 mg strength Nov. 20.
Several other drug makers, such as Teva, Mylan, Sandoz and Barr Labs, also are developing generic versions of Zyprexa.
Approval application withdrawn by Eli Lilly
INDIANAPOLIS Eli Lilly and Co. has withdrawn an application seeking approval from the Food and Drug Administration to market its antidepressant Cymbalta for treating chronic pain, the Indianapolis-based drug maker said Friday.
Citing a need for more data, Lilly said it plans to resubmit the application in the first half of next year for the added use of the drug.
“This was a difficult decision, but we believe the updated data package will give the FDA a broader basis for reviewing our application,” vice president of Lilly Research Laboratories John Hayes said in a statement.
Cymbalta (duloxetine hydrochloride) is already approved for treating depression, anxiety disorder, diabetic peripheral neuropathic pain and fibromyalgia.